Abstract
RNA-interference (RNAi) is a potent mechanism, conserved from plants to humans for specific silencing of genes, which holds promise for functional genomics and gene-targeted therapies. Here we show that bacteria engineered to produce a short hairpin RNA (shRNA) targeting a mammalian gene induce trans-kingdom RNAi in vitro and in vivo. Nonpathogenic Escherichia coli were engineered to transcribe shRNAs from a plasmid containing the invasin gene Inv and the listeriolysin O gene HlyA, which encode two bacterial factors needed for successful transfer of the shRNAs into mammalian cells. Upon oral or intravenous administration, E. coli encoding shRNA against CTNNB1 (catenin β-1) induce significant gene silencing in the intestinal epithelium and in human colon cancer xenografts in mice. These results provide an example of trans-kingdom RNAi in higher organisms and suggest the potential of bacteria-mediated RNAi for functional genomics, therapeutic target validation and development of clinically compatible RNAi-based therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
206,07 € per year
only 17,17 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Timmons, L. & Fire, A. Specific interference by ingested dsRNA. Nature 395, 854 (1998).
May, R.C. & Plasterk, R.H. RNA interference spreading in C. elegans. Methods Enzymol. 392, 308–315 (2005).
Fraser, A.G. et al. Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature 408, 325–330 (2000).
Kamath, R.S. et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421, 231–237 (2003).
Ashrafi, K. et al. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 421, 268–272 (2003).
Feinberg, E.H. & Hunter, C.P. Transport of dsRNA into cells by the transmembrane protein SID-1. Science 301, 1545–1547 (2003).
Xiang, R. et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 65, 553–561 (2005).
Milligan, J.F. & Uhlenbeck, O.C. Synthesis of small RNAs using T7 RNA polymerase. Methods Enzymol. 180, 51–62 (1989).
Milligan, J.F., Groebe, D.R., Witherell, G.W. & Uhlenbeck, O.C. Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. Nucleic Acids Res. 15, 8783–8798 (1987).
Isberg, R.R., Voorhis, D.L. & Falkow, S. Identification of invasin: a protein that allows enteric bacteria to penetrate cultured mammalian cells. Cell 50, 769–778 (1987).
Young, V.B., Falkow, S. & Schoolnik, G.K. The invasin protein of Yersinia enterocolitica: internalization of invasin-bearing bacteria by eukaryotic cells is associated with reorganization of the cytoskeleton. J. Cell Biol. 116, 197–207 (1992).
Mathew, E., Hardee, G.E., Bennett, C.F. & Lee, K.D. Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes. Gene Ther. 10, 1105–1115 (2003).
Grillot-Courvalin, C., Goussard, S., Huetz, F., Ojcius, D.M. & Courvalin, P. Functional gene transfer from intracellular bacteria to mammalian cells. Nat. Biotechnol. 16, 862–866 (1998).
Kim, T.H., Xiong, H., Zhang, Z. & Ren, B. β-Catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene 24, 597–604 (2005).
Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178 (2004).
Bridge, A.J., Pebernard, S., Ducraux, A., Nicoulaz, A.L. & Iggo, R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34, 263–264 (2003).
Hornung, V. et al. Sequence-specific potent induction o f IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263–270 (2005).
Roy, D. et al. A process for controlling intracellular bacterial infections induced by membrane injury. Science 304, 1515–1518 (2004).
Battistoni, A. et al. Increased expression of periplasmic Cu,Zn superoxide dismutase enhances survival of Escherichia coli invasive strains within nonphagocytic cells. Infect. Immun. 68, 30–37 (2000).
Rembacken, B.J., Snelling, A.M., Hawkey, P.M., Chalmers, D.M. & Axon, A.T. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354, 635–639 (1999).
Toso, J.F. et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 20, 142–152 (2002).
Bitko, V., Musiyenko, A., Shulyayeva, O. & Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11, 50–55 (2005).
Zhao, M. et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 102, 755–760 (2005).
Narayanan, K. & Warburton, P.E. DNA modification and functional delivery into human cells using Escherichia coli DH10B. Nucleic Acids Res. 31, e51 (2003).
Darji, A. et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91, 765–775 (1997).
Pawelek, J.M., Low, K.B. & Bermudes, D. Bacteria as tumour-targeting vectors. Lancet Oncol. 4, 548–556 (2003).
Miliotis, M.D. Acridine orange stain for determining intracellular enteropathogens in HeLa cells. J. Clin. Microbiol. 29, 830–831 (1991).
Acknowledgements
We thank J.T. LaMont and Y.X. Yang (Harvard Medical School) for helpful discussions, Xiangao Sun and A.J. Wang for advice and C. Grillot-Courvalin for pGB2Ωinv-hly.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.J.L. holds stock in ArQule Inc. and CeQuent Inc.
Supplementary information
Supplementary Fig. 1
Structure of Transkingdom RNA Interference Plasmid (TRIP) and silencing sequences (PDF 18 kb)
Supplementary Fig. 2
Specific silencing of β-catenin in SW 480 cells (PDF 21 kb)
Supplementary Fig. 3
Silencing is caused by bacterial produced shRNA; TRIP plasmid transfection does not induce silencing. (PDF 39 kb)
Supplementary Fig. 4
GAPDH expression is not altered by E.coli expressing shRNA against β-catenin after oral dosing in mice (PDF 367 kb)
Supplementary Table 1
RT-PCR for marker genes of interferon pathway induction (PDF 13 kb)
Rights and permissions
About this article
Cite this article
Xiang, S., Fruehauf, J. & Li, C. Short hairpin RNA–expressing bacteria elicit RNA interference in mammals. Nat Biotechnol 24, 697–702 (2006). https://doi.org/10.1038/nbt1211
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1211
This article is cited by
-
Bacterial therapies at the interface of synthetic biology and nanomedicine
Nature Reviews Bioengineering (2023)
-
Oral delivery of RNAi for cancer therapy
Cancer and Metastasis Reviews (2023)
-
Metabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors
Scientific Reports (2021)
-
In situ delivery of biobutyrate by probiotic Escherichia coli for cancer therapy
Scientific Reports (2021)
-
Dietary RNA is ripe for investigation
Nature (2020)